Urokinase
From Proteopedia
(Difference between revisions)
| Line 20: | Line 20: | ||
**[[1kdu]] – hUK kringle domain (residues 69-153) - NMR<br /> | **[[1kdu]] – hUK kringle domain (residues 69-153) - NMR<br /> | ||
**[[4dva]] – hUK catalytic domain (residues 179-431) <br /> | **[[4dva]] – hUK catalytic domain (residues 179-431) <br /> | ||
| + | **[[4xsk]] - hUK catalytic domain (mutant) <br /> | ||
*Urokinase catalytic domain complex with inhibitors | *Urokinase catalytic domain complex with inhibitors | ||
| Line 32: | Line 33: | ||
**[[1ejn]] - hUK (mutant) + urea derivative inhibitor<br /> | **[[1ejn]] - hUK (mutant) + urea derivative inhibitor<br /> | ||
**[[2vin]], [[2vio]], [[2vip]], [[2viq]], [[2viv]], [[2viw]] - hUK (mutant) + mexiletine derivative<br /> | **[[2vin]], [[2vio]], [[2vip]], [[2viq]], [[2viv]], [[2viw]] - hUK (mutant) + mexiletine derivative<br /> | ||
| - | **[[3qn7]], [[4jk5]], [[4jk6]], [[4x1n]], [[4x1q]], [[4x1r]] - hUK (mutant) + peptide inhibitor<br /> | + | **[[3qn7]], [[4jk5]], [[4jk6]], [[4x1n]], [[4x1q]], [[4x1r]], [[4x1s]], [[4x0w]], [[4x1p]], [[4zhl]], [[4zhm]], [[4zkn]], [[4zko]], [[4zkr]], [[4zks]] - hUK (mutant) + peptide inhibitor<br /> |
**[[4mnw]], [[4mnx]], [[4mny]], [[4os1]], [[4os2]], [[4os4]], [[4os5]], [[4os6]], [[4os7]] - hUK (mutant) + bicyclic peptide <br /> | **[[4mnw]], [[4mnx]], [[4mny]], [[4os1]], [[4os2]], [[4os4]], [[4os5]], [[4os6]], [[4os7]] - hUK (mutant) + bicyclic peptide <br /> | ||
**[[2vnt]], [[2r2w]] - hUK + guanidine derivative<br /> | **[[2vnt]], [[2r2w]] - hUK + guanidine derivative<br /> | ||
| Line 64: | Line 65: | ||
**[[2i9b]] - hUK Hc N terminal + UK receptor (mutant)<br /> | **[[2i9b]] - hUK Hc N terminal + UK receptor (mutant)<br /> | ||
**[[4dw2]] - hUK B chain catalytic domain + antibody<br /> | **[[4dw2]] - hUK B chain catalytic domain + antibody<br /> | ||
| + | **[[5hgg]] - hUK catalytic domain (mutant) + antibody<br /> | ||
}} | }} | ||
==References== | ==References== | ||
Revision as of 11:09, 11 December 2016
| |||||||||||
3D Structures of urokinase
Updated on 11-December-2016
References
- ↑ Carriero MV, Stoppelli MP. The urokinase-type plasminogen activator and the generation of inhibitors of urokinase activity and signaling. Curr Pharm Des. 2011;17(19):1944-61. PMID:21711235
- ↑ Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K. Urokinase-type plasminogen activator system and breast cancer (Review). Oncol Rep. 2005 Jul;14(1):105-12. PMID:15944776
- ↑ West CW, Adler M, Arnaiz D, Chen D, Chu K, Gualtieri G, Ho E, Huwe C, Light D, Phillips G, Pulk R, Sukovich D, Whitlow M, Yuan S, Bryant J. Identification of orally bioavailable, non-amidine inhibitors of Urokinase Plasminogen Activator (uPA). Bioorg Med Chem Lett. 2009 Oct 1;19(19):5712-5. Epub 2009 Aug 7. PMID:19703768 doi:10.1016/j.bmcl.2009.08.008
